KALV

KalVista Pharmaceuticals, Inc. NASDAQ

Healthcare ·Biotechnology ·US · kalvista.com

$26.66

Mkt Cap $1.4B

52w Low $9.83 99.4% of range 52w High $26.76

50d MA $18.59 200d MA $15.07

P/E (TTM) -7.2x

EV/EBITDA -3.4x

P/B 13.9x

Debt/Equity 0.1x

ROE -1065.3%

P/FCF -4.5x

RSI (14) —

ATR (14) —

Beta -0.40

50d MA $18.59

200d MA $15.07

Avg Volume 983.9K

About

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
May 5, 2026	BMO	-0.38	-0.92	-144.5%	26.66	+0.1%	—	—	—	—	—	—
Mar 24, 2026	BMO	-0.54	-1.01	-87.0%	16.46	+4.3%	+4.1%	+4.1%	+15.1%	+17.4%	+11.5%	—
Nov 10, 2025	BMO	-0.96	-0.92	+4.2%	10.89	+4.6%	+5.3%	+5.3%	+22.5%	+20.2%	+25.1%	—
Sep 11, 2025	BMO	-0.91	-1.12	-23.1%	14.81	-1.4%	-5.4%	-5.4%	-8.0%	-8.8%	-9.7%	—
Jul 10, 2025	BMO	-0.77	-0.99	-28.6%	15.51	-4.1%	-6.4%	-6.4%	-1.9%	-2.2%	+1.8%	—
Mar 12, 2025	BMO	-0.89	-0.92	-3.4%	12.45	-0.8%	-1.6%	-1.6%	+1.2%	+0.3%	-0.6%	—
Dec 5, 2024	BMO	-0.91	-0.91	+0.0%	9.06	-0.7%	+8.3%	+8.3%	+3.1%	+4.2%	+0.3%	—
Sep 5, 2024	BMO	-0.91	-0.87	+4.4%	12.87	+2.1%	-4.1%	-4.1%	-7.8%	-12.9%	-16.7%	—
Jul 11, 2024	BMO	-0.73	-1.02	-39.7%	12.50	+1.0%	+4.3%	+4.3%	+19.7%	+22.0%	+19.8%	—
Mar 11, 2024	BMO	-0.77	-0.84	-9.1%	13.10	-1.8%	-4.7%	-4.7%	-4.7%	-5.1%	-8.9%	—
Dec 7, 2023	BMO	-0.79	-0.80	-1.3%	8.97	-0.8%	-9.0%	-9.0%	-2.0%	+8.8%	+10.4%	—
Sep 7, 2023	BMO	-0.86	-0.74	+14.0%	10.84	+0.9%	-4.5%	-4.5%	-2.8%	-4.8%	-6.9%	—
Jul 7, 2023	AMC	-0.92	-0.77	+16.3%	10.29	+1.2%	+1.7%	-4.8%	-6.4%	-5.2%	-6.3%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
May 1	H.C. Wainwright	Downgrade	Buy → Neutral	$27	$26.66	$26.66	+0.0%	-0.0%	—	—	—	—
Mar 26	Stifel	Maintains	Buy → Buy	—	$17.14	$16.97	-1.0%	+10.6%	+12.8%	+7.1%	+17.4%	+15.3%
Mar 26	Citizens	Maintains	Market Outperform → Market Outperform	—	$17.14	$16.97	-1.0%	+10.6%	+12.8%	+7.1%	+17.4%	+15.3%
Mar 25	Needham	Maintains	Buy → Buy	—	$16.46	$17.17	+4.3%	+4.1%	+15.1%	+17.4%	+11.5%	+22.3%
Jan 9	Needham	Maintains	Buy → Buy	—	$15.82	$18.60	+17.6%	+6.2%	+3.6%	-5.6%	-3.7%	-5.4%
Jan 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.82	$18.60	+17.6%	+6.2%	+3.6%	-5.6%	-3.7%	-5.4%
Jan 6	Needham	Maintains	Buy → Buy	—	$15.66	$15.96	+1.9%	+0.6%	+4.3%	+1.0%	+7.3%	+4.7%
Dec 4	Needham	Maintains	Buy → Buy	—	$14.66	$14.63	-0.2%	+11.9%	+12.1%	+15.0%	+10.2%	+15.0%
Nov 11	Citizens	Maintains	Market Outperform → Market Outperform	—	$10.89	$11.39	+4.6%	+5.3%	+22.5%	+20.2%	+25.1%	+36.5%
Sep 12	Needham	Maintains	Buy → Buy	—	$14.81	$14.61	-1.4%	-5.4%	-8.0%	-8.8%	-9.7%	-6.3%
Sep 12	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$14.81	$14.61	-1.4%	-5.4%	-8.0%	-8.8%	-9.7%	-6.3%
Jul 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.51	$14.88	-4.1%	-6.4%	-1.9%	-2.2%	+1.8%	+3.2%
Jul 8	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$15.06	$15.43	+2.5%	-0.7%	+6.2%	+3.0%	-3.6%	+1.1%
Jul 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.06	$15.43	+2.5%	-0.7%	+6.2%	+3.0%	-3.6%	+1.1%
Jul 7	Leerink Partners	Maintains	Outperform → Outperform	—	$11.98	$14.02	+17.0%	+25.7%	+24.8%	+33.5%	+29.5%	+21.2%
Apr 8	Needham	Maintains	Buy → Buy	—	$11.50	$11.56	+0.5%	-10.3%	-5.9%	-8.3%	-0.1%	+3.9%
Mar 26	Citizens Capital Markets	Maintains	Market Outperform → Market Outperform	—	$12.50	$12.32	-1.4%	-3.4%	-1.3%	-4.6%	-7.7%	-10.7%
Mar 26	Needham	Maintains	Buy → Buy	—	$12.50	$12.32	-1.4%	-3.4%	-1.3%	-4.6%	-7.7%	-10.7%
Mar 26	Jones Trading	Maintains	Buy → Buy	—	$12.50	$12.32	-1.4%	-3.4%	-1.3%	-4.6%	-7.7%	-10.7%
Mar 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$12.25	$12.25	+0.0%	+2.9%	+2.0%	+1.0%	-1.2%	-2.0%
Mar 13	Needham	Maintains	Buy → Buy	—	$12.45	$12.35	-0.8%	-1.6%	+1.2%	+0.3%	-0.6%	-2.8%
Mar 3	Citizens Capital Markets	Maintains	Market Outperform → Market Outperform	—	$11.40	$11.51	+1.0%	-4.6%	-1.1%	+1.8%	+5.1%	+4.6%
Dec 9	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$9.81	$9.75	-0.6%	-4.8%	-3.8%	-7.3%	-10.9%	-11.4%
Dec 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.06	$9.00	-0.7%	+8.3%	+3.1%	+4.2%	+0.3%	-3.5%
Dec 5	Needham	Maintains	Buy → Buy	—	$9.46	$9.69	+2.4%	-4.2%	+3.7%	-1.3%	-0.2%	-3.9%
Oct 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.36	$11.27	-0.8%	-0.7%	-1.3%	-1.1%	-3.3%	+2.4%
Sep 6	Needham	Maintains	Buy → Buy	—	$12.87	$13.14	+2.1%	-4.1%	-7.8%	-12.9%	-16.7%	-18.7%
Sep 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$12.87	$13.14	+2.1%	-4.1%	-7.8%	-12.9%	-16.7%	-18.7%
Jul 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.04	$13.18	+1.1%	+14.7%	+16.9%	+14.8%	+8.9%	+11.6%
Jul 12	Needham	Maintains	Buy → Buy	—	$12.50	$12.63	+1.0%	+4.3%	+19.7%	+22.0%	+19.8%	+13.6%
Jun 18	Needham	Maintains	Buy → Buy	—	$11.82	$11.77	-0.4%	-3.8%	-5.2%	-0.7%	-0.8%	-2.3%
May 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$12.17	$12.24	+0.6%	-0.3%	-0.2%	+0.2%	-0.9%	-0.7%
May 1	Needham	Maintains	Buy → Buy	—	$11.35	$11.35	+0.0%	+7.3%	+7.2%	+6.9%	+7.0%	+7.4%
Apr 11	Needham	Maintains	Buy → Buy	—	$11.93	$11.87	-0.5%	+1.4%	-0.3%	-1.6%	-0.4%	-2.3%
Mar 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.10	$12.86	-1.8%	-4.7%	-4.7%	-5.1%	-8.9%	-8.5%
Mar 11	Needham	Maintains	Buy → Buy	—	$14.36	$14.04	-2.2%	-8.8%	-13.0%	-13.0%	-13.4%	-16.9%
Feb 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.85	$14.95	+0.7%	-3.0%	-0.6%	+0.1%	-7.1%	-12.2%
Feb 13	Needham	Maintains	Buy → Buy	—	$16.04	$15.84	-1.2%	-7.4%	-10.2%	-8.0%	-7.4%	-14.0%
Sep 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.84	$10.94	+0.9%	-4.5%	-2.8%	-4.8%	-6.9%	-8.0%
Aug 22	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$10.97	$10.97	+0.0%	+0.3%	-0.4%	-3.3%	+0.1%	-1.4%
Jul 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.29	$10.41	+1.2%	+1.7%	-4.8%	-6.4%	-5.2%	-6.3%
Mar 10	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$7.35	$7.49	+1.9%	-5.3%	+1.9%	+4.4%	+1.4%	+1.4%
Feb 3	SVB Leerink	Maintains	Outperform → Outperform	—	$7.62	$7.54	-1.0%	+3.3%	+5.9%	+9.3%	+4.1%	+0.7%
Oct 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.15	$5.17	+0.4%	-4.3%	-3.9%	-8.9%	-10.5%	-12.0%
Oct 5	SVB Leerink	Maintains	Outperform → Outperform	—	$5.85	$5.87	+0.3%	-12.0%	-15.7%	-15.4%	-19.8%	-21.2%
Oct 4	Needham	Maintains	Buy → Buy	—	$14.24	$6.99	-50.9%	-58.9%	-63.8%	-65.4%	-65.2%	-67.1%
Jul 8	Needham	Maintains	Buy → Buy	—	$10.98	$10.69	-2.6%	+0.8%	-3.6%	+7.6%	+13.2%	+9.7%
Jul 8	SVB Leerink	Maintains	Outperform → Outperform	—	$10.98	$10.69	-2.6%	+0.8%	-3.6%	+7.6%	+13.2%	+9.7%
Jun 8	Stifel	Maintains	Buy → Buy	—	$8.85	$8.73	-1.4%	-5.1%	-3.4%	-5.6%	-7.8%	-5.3%
Mar 11	Needham	Maintains	Buy → Buy	—	$16.38	$16.30	-0.5%	-6.0%	-12.2%	-11.5%	-11.8%	-6.3%

Recent Filings

8-K · 5.02 !!! Very High

Alpha Cognition Inc. -- 8-K 5.02: Executive Change

Alpha Cognition Inc. (ACOG) appointed Bethany Sensenig as a director, expanding its board composition and potentially bringing new expertise to guide the company's strategic direction.

Apr 20

8-K

Unknown — 8-K Filing

KalVista's eight-month financial results and corporate update suggest material business developments; investors should review cash position, pipeline progress, and any strategic announcements that could significantly impact the biotech company's runway and stock valuation.

Mar 25

Data updated apr 25, 2026 5:11pm · Source: massive.com